The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl

Molecular Medicine

Volumn 6, Issue 11, 2000, Pages 907-933

  Müller, Günter ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Amaryllis; Calmodulin dependent Protein Kinase II (CaMKII); Decreased Blood Glucose; Glibenclamide; Insulin mimetic Signaling

Indexed keywords

ANTIDIABETIC AGENT; CAV1 PROTEIN, HUMAN; CAVEOLIN; CAVEOLIN 1; GLIMEPIRIDE; INSULIN; SULFONYLUREA DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG EFFECT; HUMAN; MOLECULAR GENETICS; MOLECULAR MIMICRY; PANCREAS ISLET; PHYSIOLOGY; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; CAVEOLIN 1; CAVEOLINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; SULFONYLUREA COMPOUNDS;

MLCS; MLOWN;

EID: 0034327237     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.1007/BF03401827     Document Type: Review

References (140)

1. H.E. Lebovitz H. Rifkin D. Porte Oral hypoglycemic agents Ellenberg and Rifkin’s Diabetes mellitus. Theory and Practise 1990 New York Elsevier 554 574
2. S.J.H. Ashcroft F.M. Ashcroft The sulfonylurea receptor Biochim. Biophys. Acta 1992 1175 45 59 1482696 10.1016/0167-4889(92)90008-Y 1:CAS:528:DyaK3sXhtFKjtr8%3D
3. L.H. Philipson ATP-sensitive K+ channels: paradigm lost, paradigm regained Science 1995 270 1159 7502039 10.1126/science.270.5239.1159 1:CAS:528:DyaK2MXpsVykt7g%3D
4. L. Aguilar-Bryan J. Bryan Molecular biology of adenosine triphosphate-sensitive potassium channels Endocr. Rev. 1999 20 101 135 10204114 1:CAS:528:DyaK1MXisFygsro%3D
5. 2+/calmodulin-dependent protein kinase II in insulinoma MIN6 cells Endocrinology 2000 141 2350 2360 10875234 10.1210/endo.141.7.7553 1:CAS:528:DC%2BD3cXlt1Wmt7s%3D
6. R.A. Easom CaM kinase II: a protein kinase with extraordinary talents germane to insulin exocytosis Diabetes 1999 48 675 684 10102681 10.2337/diabetes.48.4.675 1:CAS:528:DyaK1MXitFCqtro%3D
7. 2+/calmodulin protein kinase II in synaptic vesicles FEBS Lett. 1993 317 85 88 8381369 10.1016/0014-5793(93)81496-M 1:CAS:528:DyaK3sXhs1egurg%3D
8. K. Matsumoto K. Ebihara H. Yamamoto et al. Cloning from insulinoma cells of synapsin I associated with insulin secretory granules J. Biol. Chem. 1999 274 2053 2059 9890964 10.1074/jbc.274.4.2053 1:CAS:528:DyaK1MXovVGgug%3D%3D
9. 2+/calmodulin-dependent protein kinase IIδ associated with insulin secretion vesicles Endocrinology 1997 138 2577 2584 10.1210/endo.138.6.5168
10. J.M. Skeer P. Degano B. Coles M. Potier F.M. Ashcroft S.J.H. Ashcroft Determination of the molecular mass of the native beta-cell sulfonylurea receptor FEBS Lett. 1994 338 98 102 8307165 10.1016/0014-5793(94)80124-X 1:CAS:528:DyaK2cXhsFentbs%3D
11. + channels Biochim. Biophys. Acta 1999 1461 285 303 10581362 10.1016/S0005-2736(99)00164-9 1:CAS:528:DyaK1MXns1agtLY%3D
12. ATP channel subunits Neuron 1997 18 827 838 9182806 10.1016/S0896-6273(00)80321-9 1:CAS:528:DyaK2sXjs1Omtr0%3D
13. L.A. Bryan C.G. Nichols S.W. Wechsler et al. Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion Science 1995 268 423 426 7716547 10.1126/science.7716547
14. KATP: an inward rectifier subunit plus the sulfonylurea receptor Science 1996 270 1167 1170
15. K. Ueda J. Komine M. Matsuo S. Seino T. Amachi Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide Proc. Natl. Acad. Sci. USA 1999 96 1268 1272 9990013 10.1073/pnas.96.4.1268 1:CAS:528:DyaK1MXhsFSrt7c%3D 15452
16. ATP channels Annu. Rev. Physiol. 1998 60 667 687 9558481 10.1146/annurev.physiol.60.1.667 1:CAS:528:DyaK1cXitVOhsbk%3D
17. R. Ashfield F.M. Gribble S.J. Ashcroft F.M. Ashcroft Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel Diabetes 1999 48 1341 1347 10342826 10.2337/diabetes.48.6.1341 1:CAS:528:DyaK1MXjsFSgt7w%3D
18. ATP channel closure FEBS Lett. 1999 459 367 376 10526167 10.1016/S0014-5793(99)01215-6 1:CAS:528:DyaK1MXmvVKjsL4%3D
19. ATP channels Physiol. Rev. 1998 78 227 245 9457174 10.1152/physrev.1998.78.1.227 1:CAS:528:DyaK1cXptlOjtw%3D%3D
20. I. Uhde A. Toman I. Gross C. Schwanstecher M. Schwanstecher Identification of the potassium channel opener site on sulfonylurea receptors J. Biol. Chem. 1999 274 28079 28082 10497157 10.1074/jbc.274.40.28079 1:CAS:528:DyaK1MXmsFWgsb8%3D
21. P.M. Thomas G.J. Cote N. Wohlik et al. Mutations in the sulfonylurea receptor gene in familial hyperinsulinemic hypoglycemia of infancy Science 1995 268 426 429 7716548 10.1126/science.7716548 1:CAS:528:DyaK2MXltFKktb0%3D
22. P. Thomas Y. Ye E. Lightner Mutations of the pancreatic islet inward rectifier also lead to familial persistent hyperinsulinemic hypoglycemia of infancy Hum. Mol. Gen. 1996 5 1809 1812 8923010 10.1093/hmg/5.11.1809 1:CAS:528:DyaK28XmslKls78%3D
23. ATP channels in pancreatic β cells causes persistent hyperinsulinemic hypoglycemia of infancy Nature Med. 1996 2 1344 1347 8946833 10.1038/nm1296-1344 1:CAS:528:DyaK28Xntlymu7k%3D
24. F.M. Gribble S.J. Tucker F.M. Ashcroft The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by MgADP and diazoxide EMBO J. 1997 16 1145 1152 9135131 1169713 10.1093/emboj/16.6.1145 1:CAS:528:DyaK2sXitlOisLk%3D
25. C.G. Nichols S.-L. Shyng A. Nestorowicz Adenosine diphosphate as an intracellular regulator of insulin secretion Science 1996 272 1785 1787 8650576 10.1126/science.272.5269.1785 1:CAS:528:DyaK28XjslWnu74%3D
26. S.-L. Shyng T. Ferrigni J.B. Sheppard Functional analysis of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy Diabetes 1998 47 1145 1151 9648840 10.2337/diabetes.47.7.1145 1:CAS:528:DyaK1cXkt1amtbc%3D
27. G. Müller D. Hartz J. Pünter R. Ökonomopulos W. Kramer Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor: I. Binding characteristics Biochim. Biophys. Acta 1994 1191 267 277 8172912 10.1016/0005-2736(94)90177-5
28. W. Kramer G. Müller F. Girbig et al. The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels Diabetes Res. Clin. Pract. 1995 28 Suppl. S67 S80 8529521 10.1016/0168-8227(95)01076-P 1:CAS:528:DyaK2MXoslKns78%3D
29. 3H]glimepiride Biochim. Biophys. Acta 1994 1191 278 290 8172913 10.1016/0005-2736(94)90178-3 1:CAS:528:DyaK2cXjtFGmtb0%3D
30. W. Kramer K. Geisen G. Müller Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at pancreatic β-cells Horm. Metab. Res. 1996 28 464 468 8911984 10.1055/s-2007-979838 1:CAS:528:DyaK28XntVOnsbw%3D
31. 3H]glibenclamide FEBS Lett. 1988 229 355 359 2831099 10.1016/0014-5793(88)81155-4 1:CAS:528:DyaL1cXhsl2qtr0%3D
32. F.M. Ashcroft Mechanisms of the glycaemic effects of sulfonylureas Horm. Metab. Res. 1996 28 456 463 8911983 10.1055/s-2007-979837 1:CAS:528:DyaK28XntVOnsb8%3D
33. F.M. Ashcroft F.M. Gribble ATP-sensitive K+ channels and insulin secretion: their role in health and disease Diabetologia 1999 42 903 919 10491749 10.1007/s001250051247 1:CAS:528:DyaK1MXkvF2ksLg%3D
34. E. Draeger Clinical profile of glimepiride Diabetes Res. Clin. Pract. 1995 28 S139 S146 8529506 10.1016/0168-8227(95)01072-L 1:CAS:528:DyaK2MXoslKns7Y%3D
35. H.D. Langtry J.A. Balfour Glimepiride—a review of its pharmacological and clinical efficacy in the management of type 2 diabetes mellitus Drugs 1998 55 563 584 9561345 10.2165/00003495-199855040-00007 1:CAS:528:DyaK1cXisFyjs7Y%3D
36. K. Tsumura Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide Diabetes Res. Clin. Pract. 1995 28 S147 S149 8529507 10.1016/0168-8227(95)01104-L 1:CAS:528:DyaK2MXoslKns7c%3D
37. D.G. Dills J. Schneider Glimepiride/Glyburide Research Group Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study Horm. Metab. Res. 1996 28 426 429 8911977 10.1055/s-2007-979831 1:CAS:528:DyaK28XntVOnsLs%3D
38. K.E. Draeger K. Wernicke-Panten H.J. Lomp Long-term treatment of type 2 diabetic patients with a new oral anti-diabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide Horm. Metab. Res. 1996 28 419 425 8911976 10.1055/s-2007-979830 1:CAS:528:DyaK28XntVOnsLo%3D
39. G. Müller Y. Satoh K. Geisen Extrapancreatic effects of sulfonylureas — a comparison between glimepiride and conventional sulfonylureas Diabetes Res. Clin. Pract. 1995 28 Suppl. S115 S137 8529504 10.1016/0168-8227(95)01089-V
40. G. Müller K. Geisen Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes Horm. Metab. Res. 1996 28 469 487 8911985 10.1055/s-2007-979839
41. K. Geisen Special pharmacology of the new sulfonylurea glimepiride Drug. Res. 1988 38 1120 1130 1:CAS:528:DyaL1cXls1ehtLo%3D
42. G. Müller S. Wied E.-M. Wetekam A. Crecelius A. Unkelbach J. Pünter Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade Biochem. Pharmacol. 1994 48 985 996 8093111 10.1016/0006-2952(94)90369-7
43. M.B. Davidson G. Molnar A. Furman D. Yamaguchi Glyburide-stimulated glucose transport in cultured muscle cells via protein kinase C-mediated pathway requiring new protein synthesis Diabetes 1991 40 1531 1538 1936611 10.2337/diab.40.11.1531 1:CAS:528:DyaK38XlsVM%3D
44. 3H-1 myocyte Diabetes 1987 36 1292 1296 3117607 10.2337/diab.36.11.1292 1:CAS:528:DyaL1cXhs1WhsQ%3D%3D
45. J.F. Bak O. Schmitz N.S. Sorensen O. Pedersen Post-receptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients Diabetes 1989 38 1343 1350 2559864 10.2337/diabetes.38.11.1343 1:CAS:528:DyaK3cXkvFA%3D
46. D.B. Jacobs C.Y. Jung Sulfonylurea potentiates insulin-induced recruitment of glucose transport carrier in rat adipocytes J. Biol. Chem. 1985 260 2593 2596 3919003 1:CAS:528:DyaL2MXhslyqsbY%3D
47. N. Altan V.M. Altan L. Mikolay J. Larner C.F.W. Schwartz Insulin-like and insulin-enhancing effects of the sulfonylurea glyburide on rat adipose glycogen synthase Diabetes 1985 34 281 286 3918901 10.2337/diab.34.3.281 1:CAS:528:DyaL2MXhs1ShtbY%3D
48. D.B. Jacobs C.Y. Jung Sulfonylurea potentiates insulin-induced recruitment of glucose transport carrier in rat adipocytes J. Biol. Chem. 1985 260 2593 2596 3919003 1:CAS:528:DyaL2MXhslyqsbY%3D
49. A. Martz I. Jo C.Y. Jung Sulfonylurea binding to adipocyte membrane and potentiation of insulin stimulated hexose transport J. Biol. Chem. 1988 264 13672 13678
50. B.L. Maloff D.H. Lockwood In vitro effects of a sulfonylurea on insulin action in adipocytes J. Clin. Invest. 1981 68 85 90 7019248 370775 10.1172/JCI110257 1:CAS:528:DyaL3MXkvFSru78%3D
51. G. Müller S. Wied The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro Diabetes 1993 42 1852 1867 8243832 10.2337/diab.42.12.1852
52. J.E. Pessin D.C. Thurmond J.S. Elmendorf K.J. Coker S. Okada Molecular basis of insulin-stimulated GLUT4 vesicle trafficking J. Biol. Chem. 1999 274 2593 2596 9915783 10.1074/jbc.274.5.2593 1:CAS:528:DyaK1MXpsVegsw%3D%3D
53. G.D. Holman M. Kasuga From receptor to transporter: insulin signalling to glucose transport Diabetologia 1997 40 991 1003 9300235 10.1007/s001250050780 1:CAS:528:DyaK2sXlvVOru78%3D
54. M.P. Czech S. Corvera Signaling mechanisms that regulate glucose transport J. Biol. Chem. 1999 274 1865 1868 9890935 10.1074/jbc.274.4.1865 1:CAS:528:DyaK1MXovVGjuw%3D%3D
55. M. Bähr M. v. Holtey G. Müller J. Eckel Direct stimulation of myocardial glucose transport and glucose transporter (Glut1) and Glut4 protein expression by the sulfonylurea glimepiride Endocrinology 1995 136 2547 2553 7750476 10.1210/endo.136.6.7750476
56. J. Eckel Direct effects of glimepiride on protein expression of cardiac glucose transporters Horm. Metab. Res. 1996 28 508 511 8911988 10.1055/s-2007-979842 1:CAS:528:DyaK28XntVOnsbg%3D
57. T.A. Gustafson S.A. Moodie B.E. Lavan et al. Blaustein Greger Grunicke et al. The insulin receptor and metabolic signaling Reviews in Physiology, Biochemistry and Pharmacology 1999 Berlin Springer 71 192 vol. 137
58. M.F. White The insulin signalling system and the IRS proteins Diabetologia 1997 40 S2 S17 9248696 10.1007/s001250051387 1:CAS:528:DyaK2sXksFems78%3D
59. M.F. White The IRS-signalling system: a network of docking proteins that mediate insulin action Mol. Cell. Biochem. 1998 182 3 11 9609109 10.1023/A:1006806722619 1:CAS:528:DyaK1cXjtlOnsr4%3D
60. P.J. Coffer J. Jin J.R. Woodgett Protein kinase B (c-Akt): a multifunctional mediator of phosphatidyl 3-kinase activation Biochem. J. 1998 335 1 13 9742206 1219745 10.1042/bj3350001 1:CAS:528:DyaK1cXms1Ohur4%3D
61. P. Cohen D.R. Alessi D.A.E. Cross PDK1, one of the missing links in insulin signal transduction? FEBS Lett. 1997 410 3 10 9247112 10.1016/S0014-5793(97)00490-0 1:CAS:528:DyaK2sXkt1Shurs%3D
62. M.F. White The IRS-signalling system: a network of docking proteins that mediate insulin action Mol. Cell. Biochem. 1998 182 3 11 9609109 10.1023/A:1006806722619 1:CAS:528:DyaK1cXjtlOnsr4%3D
63. P.R. Shepherd D.J. Withers K. Siddle Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling Biochem. J. 1998 333 471 490 9677303 1219607 10.1042/bj3330471 1:CAS:528:DyaK1cXlsVWnsL4%3D
64. F.H. Nystrom M.J. Quon Insulin signalling: Metabolic pathways and mechanisms for specificity Cell. Signal. 1999 11 563 574 10433517 10.1016/S0898-6568(99)00025-X 1:CAS:528:DyaK1MXkt1ems78%3D
65. E. Araki M.A. Lipes M.E. Patti et al. Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene Nature 1994 372 186 190 7526222 10.1038/372186a0 1:CAS:528:DyaK2cXmvFehu7Y%3D
66. H. Tamemoto T. Kadowaki K. Tobe et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1 Nature 1994 372 182 186 7969452 10.1038/372182a0 1:CAS:528:DyaK2cXmvFehu7k%3D
67. D.J. Withers J.S. Gutierrez H. Towery et al. Disruption of IRS-2 causes type 2 diabetes in mice Nature 1998 391 900 904 9495343 10.1038/36116 1:CAS:528:DyaK1cXhsFyksr0%3D
68. B.E. Lavan V.R. Fantin E.T. Chang W.S. Lane S.R. Keller G.E. Lienhard A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family J. Biol. Chem. 1997 272 21403 21407 9261155 10.1074/jbc.272.34.21403 1:CAS:528:DyaK2sXls1Ojurk%3D
69. S.C.H. Liu Q. Wang G.E. Lienhard S.R. Keller Insulin receptor substrate 3 is not essential for growth or glucose homeostasis J. Biol. Chem. 1999 274 18093 18099 10364263 10.1074/jbc.274.25.18093 1:CAS:528:DyaK1MXktVylt70%3D
70. Y. Takada Y. Takata M. Iwanishi et al. Effect of glimepiride (HOE490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse Eur. J. Pharmacol. 1996 308 205 210 8840133 10.1016/0014-2999(96)00288-9 1:CAS:528:DyaK28Xkt12rtLY%3D
71. O. Nosjean A. Briolay B. Roux Mammalian GPI proteins: sorting, membrane residence and functions Biochim. Biophys. Acta 1997 1331 153 186 9325440 10.1016/S0304-4157(97)00005-1 1:CAS:528:DyaK2sXlt1Gntbw%3D
72. G. Müller E.-A. Wetekam C. Jung W. Bandlow Membrane association of lipoprotein lipase and a cAMP-binding ectoprotein in rat adipocytes Biochemistry 1994 33 12149 12159 7918436 10.1021/bi00206a018
73. G. Müller E.-A. Dearey J. Pünter The sulfonylurea drug, glimepiride, stimulates release of glycosyl-phosphatidylinositolanchored plasma membrane proteins from 3T3 adipocytes Biochem. J. 1993 289 509 521 7678737 1132197 10.1042/bj2890509
74. A.R. Saltiel J.A. Fox P. Sherline P. Cuatrecasas Insulin stimulates the generation from hepatic plasma membranes of modulators derived from an inositol glycolipid Science 1986 233 967 972 3016898 10.1126/science.3016898 1:CAS:528:DyaL28XlsVKksr4%3D
75. G.L. Romero L. Luttrell A. Rogol K. Zeller E. Hewlett J. Larner Phosphatidylinositol-glycan anchors of membrane proteins: potential precursors of insulin mediators Science 1988 240 509 511 3282305 10.1126/science.3282305 1:CAS:528:DyaL1cXhvFyksLs%3D
76. G. Müller E.-A. Dearey A. Korndörfer W. Bandlow Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport J. Cell Biol. 1994 126 1267 1276 8063863 10.1083/jcb.126.5.1267
77. S. Movahedi N. Hooper Insulin stimulates the release of the glycosyl phosphatidylinositol-anchored membrane dipeptidase from 3T3-L1 adipocytes through the action of a phospholipase C Biochem. J. 1997 326 531 537 9291128 1218701 10.1042/bj3260531 1:CAS:528:DyaK2sXmt1Gisbk%3D
78. R.G.W. Anderson The caveolae membrane system Annu. Rev. Biochem. 1998 67 199 225 9759488 10.1146/annurev.biochem.67.1.199 1:CAS:528:DyaK1cXlsFOmsL0%3D
79. M.P. Lisanti P.E. Scherer Z.L. Tang M. Sargiacomo Caveolae, caveolin and caveolin-rich membrane domains: A signaling hypothesis Trends Cell Biol. 1994 4 231 235 14731661 10.1016/0962-8924(94)90114-7 1:CAS:528:DyaK2MXjsVyrtQ%3D%3D
80. K.G. Rothberg J.E. Henser W.C. Donzell Y.-S. Ying J.R. Glenney R.G.W. Anderson Caveolin, a protein component of caveolae membrane coats Cell 1992 68 673 682 1739974 10.1016/0092-8674(92)90143-Z 1:CAS:528:DyaK38XhvFWnurY%3D
81. R.G. Parton Caveolae and caveolins Curr. Opin. Cell Biol. 1996 8 542 548 8791446 10.1016/S0955-0674(96)80033-0 1:CAS:528:DyaK28Xks1Gquro%3D
82. T.V. Kurzchalia P. Dupree S. Monier VIP-21 Caveolin, a protein of the trans-Golgi network and caveolae FEBS Lett. 1994 346 88 91 8206165 10.1016/0014-5793(94)00466-8 1:CAS:528:DyaK2cXlt1OqsLc%3D
83. K. Das R.Y. Lewis P.E. Scherer M.P. Lisanti The membrane-spanning domains of caveolins-1 and -2 mediate the formation of caveolin hetero-oligomers J. Biol. Chem. 1999 274 18721 18728 10373486 10.1074/jbc.274.26.18721 1:CAS:528:DyaK1MXkt1Sisb0%3D
84. M. Sargiacomo P.E. Scherer Z. Tang E. Kübler K.S. Song M.C. Sanders Oligomeric structure of caveolin: Implications for caveolae membrane organizations Proc. Natl. Acad. Sci. USA 1995 92 9407 9411 7568142 10.1073/pnas.92.20.9407 1:CAS:528:DyaK2MXosVWlu7w%3D 40994
85. D.A. Brown E. London Breakthroughs and views. Structure of detergent-resistant membrane domains: does phase separation occur in biological membranes? Biochem. Biophys. Res. Commun. 1997 240 1 7 9367871 10.1006/bbrc.1997.7575 1:CAS:528:DyaK2sXnsVWjsLs%3D
86. T. Okamoto A. Schlegel P.E. Scherer M.P. Lisanti Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane J. Biol. Chem. 1998 273 5419 5422 9488658 10.1074/jbc.273.10.5419 1:CAS:528:DyaK1cXhslejsbc%3D
87. A. Schlegel D. Volonte J.A. Engelmann Crowded little caves: structure and function of caveolae Cell. Signal. 1999 10 457 463 10.1016/S0898-6568(98)00007-2
88. G. Müller W. Frick Signalling via caveolin: Involvement in the cross-talk between phosphoinositolglycans and insulin Cell. Mol. Life Sci. 1999 56 945 970 11212327 10.1007/s000180050485
89. S. Li J. Couet M.P. Lisanti Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases J. Biol. Chem. 1996 272 29182 29190 10.1074/jbc.271.46.29182
90. J. Couet M. Sargiacomo M.P. Lisanti Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities J. Biol. Chem. 1997 272 30429 30438 9374534 10.1074/jbc.272.48.30429 1:CAS:528:DyaK2sXnslGgs74%3D
91. J. Couet S. Li T. Okamoto T. Ikezu M.P. Lisanti Identification of peptide and protein ligands for the caveolin-scaffolding domain J. Biol. Chem. 1997 272 6525 6533 9045678 10.1074/jbc.272.10.6525 1:CAS:528:DyaK2sXhvVOlsro%3D
92. N. Pulido A. Casla A. Suarez B. Casanova F.J. Arrieta A. Rovira Sulphonylurea stimulates glucose uptake in rats through an ATP-sensitive K+ channel dependent mechanism Diabetologia 1996 39 22 27 8720599 1:CAS:528:DyaK28Xhtlynu7c%3D
93. H. Shi N. Moustaid-Moussa W.O. Wilkison M.B. Zemel Role of the sulfonylurea receptor in regulating human adipocyte metabolism FASEB J. 1999 13 1833 1838 10506587 10.1096/fasebj.13.13.1833 1:CAS:528:DyaK1MXms1Ohs70%3D
94. A. Rajan Z.-T. Luo B.B. Kahn J.P. Comstock S.W. Cushman A.E. Boyd III Do adipocytes contain high affinity sulfonylurea receptors? Endocrinology 1994 134 1581 1588 8119201 10.1210/endo.134.3.8119201 1:CAS:528:DyaK2cXitlGrt7s%3D
95. B. Draznin K.E. Sussman R.H. Eckel M. Kao T. Yost N.A. Sherman Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperin-sulinemia J. Clin. Invest. 1988 82 1848 1852 3143744 442763 10.1172/JCI113801 1:CAS:528:DyaL1MXlsFCjtQ%3D%3D
96. 2+ concentration in isolated rat adipocytes Diabetes 1987 36 174 177 2433175 10.2337/diab.36.2.174 1:CAS:528:DyaL2sXhtFeqs7Y%3D
97. J.H. Kim L.L. Kiefer R.P. Woychik et al. Agouti regulation of intracellular clacium. Role of melanocortin receptor Am. J. Physiol. 1997 272 E379 E384 9124542 1:CAS:528:DyaK2sXit1Sku78%3D
98. M.B. Zemel L.L. Kim R.P. Woychik et al. Agouti regulation of intracellular calcium: role in the insulin resistance of viable yellow mice Proc. Natl. Acad. Sci. U.S.A. 1995 92 4733 4737 7761392 41781 10.1073/pnas.92.11.4733 1:CAS:528:DyaK2MXlvFyju7k%3D
99. ATP channels Diabetes 1998 47 1412 1418 9726229 10.2337/diabetes.47.9.1412 1:CAS:528:DyaK1cXls12qsL0%3D
100. P. Smits T. Thien Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM Diabetologia 1995 38 116 122 7744216 10.1007/BF02369361 1:CAS:528:DyaK2MXktFOjtbo%3D
101. G. Leibowitz E. Cerasi Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996 39 503 515 8739909 10.1007/BF00403296 1:CAS:528:DyaK28XjtlSis70%3D
102. UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type II diabetes (UKPDS 33) Lancet 1998 352 837 853 10.1016/S0140-6736(98)07019-6
103. S. Isomoto C. Kondo M. Yamada A novel sulphonylurea receptor forms with BIR (KIR6.2) a smooth muscle type of ATP-sensitive K+ channels J. Biol. Chem. 1996 271 24321 24325 8798681 10.1074/jbc.271.40.24321 1:CAS:528:DyaK28XmtFeisb4%3D
104. C. Ämmälä A. Moorhouse F.M. Gribble Promiscuous coupling between the sulphonylurea receptor and inwardly-rectifying potassium channels Nature 1996 379 545 548 8596634 10.1038/379545a0
105. 3H]glibenclamide binding to sulfonylurea receptors by oral antidiabetics Drug Res. 1985 35 707 712 1:CAS:528:DyaL2MXkvVWmsbs%3D
106. A. Dunn-Meynell N. Rawson B. Levin Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain Brain Res. 1998 814 41 54 9838037 10.1016/S0006-8993(98)00956-1 1:CAS:528:DyaK1cXnsFWltL0%3D
107. D. Spanswick M. Smith V. Groppi S. Logam M.L. Ashford Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels Nature 1997 390 521 525 9394003 10.1038/37379 1:CAS:528:DyaK2sXnvF2ntbc%3D
108. J. Harvey F. McKenna P.S. Herson D. Spanswick M.L. Ashford Leptin activates ATP-sensitive potassium channels in the rat insulin-secreting cell line, CRI-G1 J. Physiol. 1997 504 527 535 9401961 1159957 10.1111/j.1469-7793.1997.527bd.x 1:CAS:528:DyaK2sXnsF2ktLw%3D
109. R.V. Considine J.F. Caro Leptin and the regulation of body weight Int. J. Biochem. Cell Biol. 1997 29 1255 1272 9451823 10.1016/S1357-2725(97)00050-2 1:CAS:528:DyaK1cXltFejtQ%3D%3D
110. L.A. Tartaglia The leptin receptor J. Biol. Chem. 1997 272 6093 6096 9102398 10.1074/jbc.272.10.6093 1:CAS:528:DyaK2sXhvVOnsb4%3D
111. M.W. Schwartz S.C. Woods D. Porte R.J. Seeley D.G. Baskin Central nervous system control of food intake Nature 2000 404 661 671 10766253 10.1038/35007534 1:CAS:528:DC%2BD3cXis1Grur4%3D
112. J. Harvey M.L. Ashford Diazoxide- and leptin-activated K(ATP) currents exhibit differential sensitivity to englitazone and ciclazindol in the rat CRI-G1 insulin-secreting cell line Brit. Pharmacol. 1998 124 1557 1565 10.1038/sj.bjp.0702000 1:CAS:528:DyaK1cXlsVWmsr4%3D
113. J. Harvey M.L. Ashford Role of tyrosine phosphorylation in leptin activation of ATP-sensitive K+ channels in the rat insulinoma cell line CRI-G1 J. Physiol. 1998 510 47 61 9625866 2231029 10.1111/j.1469-7793.1998.047bz.x 1:CAS:528:DyaK1cXkvVKksrk%3D
114. J. Harvey M.L. Ashford Insulin occludes leptin activation of ATP-sensitive K+ channels in rat CRI-G1 insulin secreting cells J. Physiol. 1998 511 695 706 9714853 2231169 10.1111/j.1469-7793.1998.695bg.x 1:CAS:528:DyaK1cXmvVOrtb4%3D
115. C.C. Mastick M.J. Brady A.R. Saltiel Insulin stimulates the tyrosine phosphorylation of caveolin J. Cell Biol. 1995 129 1523 1531 7540611 10.1083/jcb.129.6.1523 1:CAS:528:DyaK2MXmt1antrw%3D
116. M.J.A. Saad L.A. Velloso C.R.O. Carvalho Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart Biochem. J. 1995 310 741 744 7575404 1135960 10.1042/bj3100741 1:CAS:528:DyaK2MXot1akt78%3D
117. A. Kowalski-Chauvel L. Pradayrol N. Vaysse C. Seva Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase J. Biol. Chem. 1996 271 26356 26361 8824290 10.1074/jbc.271.42.26356 1:CAS:528:DyaK28XmsVCltrs%3D
118. L.S. Argetsinger G.W. Hsu M.G. Myers N. Billestrup M.F. White C. Carter-Su Growth hormone, interferon-γ, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1 J. Biol. Chem. 1995 270 14685 14692 7782332 10.1074/jbc.270.24.14685 1:CAS:528:DyaK2MXmsVSiurs%3D
119. F. Verdier S. Chretien C. Billat S. Gisselbrecht C. Lacombe P. Mayeux Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2 J. Biol. Chem. 1997 272 26173 26178 9334184 10.1074/jbc.272.42.26173 1:CAS:528:DyaK2sXmvV2jurc%3D
120. D.F. Lazar J.J. Knez M.E. Medof P. Cuatrecasas A.R. Saltiel Stimulation of glycogen synthesis by insulin in human erythroleukemia cells requires the synthesis of glycosyl-phosphatidylinositol Proc. Natl. Acad. Sci. USA 1994 91 9665 9669 7524086 10.1073/pnas.91.21.9665 1:CAS:528:DyaK2cXmsVKrs7w%3D 44877
121. D.R. Jones I. Varela-Nieto The role of glycosyl-phosphatidylinositol in signal transduction Int. J. Biochem. Cell Biol. 1998 30 313 326 9611774 10.1016/S1357-2725(97)00144-1 1:CAS:528:DyaK1cXjtlWhurg%3D
122. D.R. Jones I. Varela-Nieto Diabetes and the role of inositol-containing lipids in insulin signaling Mol. Med. 1999 5 505 514 10501653 2230454 1:CAS:528:DyaK1MXntVWjtro%3D 10.1007/BF03401978
123. J. Larner L.C. Huang Identification of a novel inositol glycan signaling pathway with significant therapeutic relevance to insulin resistance: an insulin signaling model using both tyrosine kinase and G-proteins Diabetes Rev. 1999 V7N3 217 231
124. W. Frick A. Bauer J. Bauer S. Wied G. Müller Structure-activity relationship of synthetic phosphoinositolglycans mimicking metabolic insulin action Biochemistry 1998 38 13421 13436 10.1021/bi9806201
125. W. Frick A. Bauer J. Bauer S. Wied G. Müller Insulin-mimetic signalling of synthetic phosphoinositolglycans in isolated rat adipocytes Biochem. J. 1998 336 163 181 9806898 1219855 10.1042/bj3360163 1:CAS:528:DyaK1cXotVGltLo%3D
126. G. Müller S. Wied C. Piossek A. Bauer J. Bauer W. Frick Convergence and divergence of the signaling pathways for insulin and phosphoinositolglycans Mol. Med. 1998 4 299 323 9642681 10.1007/BF03401738
127. Lyn non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes Mol. Cell. Biol. 2000 20 4708 4723 10848597 85892 10.1128/MCB.20.13.4708-4723.2000
128. M. Badian A. Korn K.-H. Lehr Absolute bioavailability of glimepiride (Amaryl registered) after oral administration Drug Metab. Drug Interact. 1994 11 331 339 10.1515/DMDI.1994.11.4.331 1:CAS:528:DyaK2MXnvFeqsL4%3D
129. B. Rosenkranz V. Profozic Z. Metelko Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment Diabetologia 1996 39 1617 1624 8960852 10.1007/s001250050624 1:CAS:528:DyaK28XnsVGrsL4%3D
130. K.H. Lehr P. Damm Simultaneous determination of the sulfonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization J. Chromatogr. 1990 526 497 505 2361988 10.1016/S0378-4347(00)82531-1 1:CAS:528:DyaK3cXktVSjtrY%3D
131. K. Wernicke-Panten E. Haupt C. Pfeiffer Early onset of pharmacodynamic effects of glimepiride in type II diabetic patients Diabetologia 1994 37 Suppl. 1 163 [abstract]
132. J. Rosenstock E. Samols D.B. Muchmore Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients Diabetes Care 1996 19 1194 1199 8908379 10.2337/diacare.19.11.1194 1:STN:280:DyaK2s%2FmsVyhuw%3D%3D
133. G.E. Sonnenberg D.C. Garg D.J. Weidler Short-term comparison of once-versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus Ann. Pharmacother. 1997 31 671 676 9184703 10.1177/106002809703100601 1:CAS:528:DyaK2sXktVyktLc%3D
134. K. Geisen A. Vegh E. Krause Cardiovascular effects of conventional sulfonylureas and glimepiride Horm. Metab. Res. 1996 28 496 507 8911987 10.1055/s-2007-979841 1:CAS:528:DyaK28XntVOnsbs%3D
135. G. Ballagi-Pordany M. Nemeth Z. Aranyi Effect of glimepiride on the electrical activity of isolated rabbit heart muscle Drug Res. 1992 42 111 113 1:CAS:528:DyaK38XhvVOlu7k%3D
136. G. Müller J. Ertl M. Gerl G. Preibisch Leptin impairs metabolic actions of insulin in isolated rat adipocytes J. Biol. Chem. 1997 272 10585 10593 9099705 10.1074/jbc.272.16.10585
137. G. Müller S. Wied A. Crecelius A. Kessler J. Eckel Phosphoinositolglycan-peptides from yeast potently induce metabolic insulin actions in isolated rat adipocytes, cardiomyocytes, and diaphragms Endocrinology 1997 138 3459 3475 9231801 10.1210/endo.138.8.5308
138. 2+ indicators with greatly improved fluorescent properties J. Biol. Chem. 1985 260 3440 3450 3838314 1:CAS:528:DyaL2MXitVSmu7s%3D
139. N. Zerangue B. Schwappach Y.N. Jan L.Y. Jan A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K(ATP) channels Neuron 1999 22 537 548 10197533 10.1016/S0896-6273(00)80708-4 1:CAS:528:DyaK1MXit1emtrg%3D
140. G. Müller S. Wied S. Welte Involvement of caveolae in insulin-mimetic signaling by the sulfonylurea Amaryl Chem. Phys. Lipids 2000 7 7 8 [abstract]